### Table S1 Univariate and multivariate analyses of predictors associated with SVI (containing CAPRA score)

| Variable | Univariate | Multivariate |
|----------|------------|--------------|
|          | OR (95% CI) | P value      | OR (95% CI) | P value |
| Age (y)  | 0.990 (0.944–1.039) | 0.694 |           |          |
| BMI (kg/m²) | 1.038 (0.903–1.193) | 0.599 |           |          |
| PSA (ng/mL) | 1.211 (0.955–1.536) | 0.114 |           |          |
| f/t PSA  | 0.014 (0.000–25.202) | 0.266 |           |          |
| PV (mL)  | 0.984 (0.962–1.006) | 0.150 |           |          |
| PSAD (ng/mL²) | 12.465 (0.477–325.419) | 0.130 |           |          |
| The percentage of positive systematic biopsies | 1.019 (1.002–1.036) | 0.028* |           |          |
| Maximum cancer percentage per core | 1.019 (1.003–1.035) | 0.018* | 0.170 |          |
| Clinical stage, No. (%) | 1.113 (0.806–1.594) | 0.473 |           |          |
| T1c      |            |          |           |          |
| T2a      |            |          |           |          |
| T2b      |            |          |           |          |
| T2C      |            |          |           |          |
| T3a      |            |          |           |          |
| CAPRA score | 1.388 (1.063–1.814) | 0.016* | 0.179 |          |
| PI-RADS  | 4.095 (1.688–9.938) | 0.002* | 4.095 (1.688–9.938) | 0.002* |
| Negative |            |          |           |          |
| Suspicious |            |          |           |          |
| Positive |            |          |           |          |
| GGG      | 1.747 (1.284–2.378) | <0.001* |          |          |
| 1        |            |          |           |          |
| 2        |            |          |           |          |
| 3        |            |          |           |          |
| 4        |            |          |           |          |
| 5        |            |          |           |          |

SVI, seminal vesicle invasion; OR, odd ratios; CI, confidence interval; BMI, body mass index; PSA, prostate-specific antigen; f/t PSA, free/total prostate-specific antigen ratio; PV, prostate volume; PSAD, PSA density; CAPRA, cancer of the prostate risk assessment; PI-RADS, Prostate Imaging Reporting and Data System; GGG, Gleason grade group; *, P value with <0.05 significance.